Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
US9682092
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
US8501712
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(4 years from now) | |
US8039451
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(6 years from now) | |
US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(6 years from now) | |
US8168614
(Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Mar 23, 2023 |
Pediatric Exclusivity (PED) | Sep 23, 2023 |
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
47
United States
13
Japan
12
Korea, Republic of
9
China
7
European Union
6
Portugal
6
Russia
6
Spain
6
Hungary
6
Poland
5
Hong Kong
5
South Africa
5
Slovenia
5
Israel
5
Australia
5
Denmark
4
New Zealand
4
Mexico
4
Canada
4
Cyprus
3
Brazil
1
Croatia
1
Lithuania
1
Luxembourg
1
ME
1
RS
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic